The Effects Of HMO On The Faecal Microbiota And On Gastrointestinal Symptoms In Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a randomised, placebo-controlled, double-blind, parallel, dose-finding study with healthy volunteers. A total of 100 male and female volunteers will be included. The volunteers will be randomized into one of 10 groups, each of 10 participants, consuming either active product in various mixes and doses (9 groups) or placebo product (1 group) for 2 weeks. The 9 groups receiving active product will receive either one of two Human Milk Oligosaccharides (HMOs) alone or in combination at different doses. The primary purpose of the study is establishing the effects of various compositions and doses of HMOs on the faecal flora and on gastrointestinal symptoms in health adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients

NCT02875847

Irritable Bowel Syndrome (IBS)

COMPLETED PHASE2

Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients

NCT03550742

Irritable Bowel Syndrome (IBS)

COMPLETED NA

Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms

NCT06889779

IBS (Irritable Bowel Syndrome)

RECRUITING NA

An Intervention Study Using HMOs to Improve IBS Symptoms

NCT06281600

Irritable Bowel Syndrome

RECRUITING NA

Human Milk Oligosaccharides (HMOs) for Irritable Bowel Syndrome (IBS)

NCT05205785

Irritable Bowel Syndrome IBS - Irritable Bowel Syndrome

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gut Microbiota Gastrointestinal Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

Intervention Type DIETARY_SUPPLEMENT

HMO9

HMO diluted in water

Group Type ACTIVE_COMPARATOR

HMO

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HMO

Intervention Type DIETARY_SUPPLEMENT

Glucose

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed written informed consent
* Ability and willingness to understand and comply to the study procedures

Exclusion Criteria

* Participation in a clinical study one month prior to screening visit and throughout the study.
* Abnormal results of the screening laboratory tests clinically relevant for study participation, as judged by the investigator.
* Any gastrointestinal symptom scored \>3 on the GSRS during the screening period
* A mean score on the total GSRS \>2 (i.e. above the population norm value) during the screening period
* Any gastrointestinal disease(s) that may cause symptoms or may interfere with the trial outcome, as judged by the investigator.
* Other severe disease(s) such as malignancy, diabetes, severe coronary disease, kidney disease or neurological disease, as judged by the investigator.
* Severe psychiatric disease, as judged by the investigator.
* Use of highly dosed probiotic supplements (yoghurt allowed) 3 months prior to the study and throughout the study.
* Consumption of antibiotic drugs 3 months prior to screening and throughout the study.
* Consumption on a regular basis of medication that might interfere with symptom evaluation (as judged by the investigator) 2 weeks prior to screening and throughout the study.
* Pregnant or lactating or wish to become pregnant during the period of the study.
* Lack of suitability for participation in the study for any reason as judged by the investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes